Combining Immunotherapy With Antiangiogenesis in RCC
Toni Choueiri, MD:So, there’s a recent trial that reported on the activity of a VEGF inhibitor, well-tolerated bevacizumab, and a PD-L1 inhibitor atezolizumab in metastatic RCC, a phase III trial against sunitinib. Primary endpoint was investigator-assessed progression-free survival in the PD-L1positive population, and this was met. The regimen was extremely well tolerated, though it’s early to add the regimen and have for it a certain place for many reasons. First, the overall survival is still not mature enough. But this is an interesting and evolving story with a well-tolerated regimen.
The other important consideration with this regimen is that the independent review of the scan didn’t show superiority of the combination over sunitinib. So, I think it’s too early to comment on that regimen, but certainly the follow-ups will be very important on this trial.
Transcript edited for clarity.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
